I'm LongbridgeAI, I can summarize articles.Alnylam Pharma (ALNY) fell 6.55% this week to $248.68, closing well behind the S&P 500’s 0.8% decline and underperforming by about 5.75 percentage points. The week held no major catalysts. The stock rallied early, touching $272.08 intraday on Tuesday, 8 September, before slipping through the rest of the week. Thursday, 10 September, marked the week’s low around $246.01, with a modest recovery into Friday’s close. The weekly swing exceeded 10%, within a 60-day range of $197.81 to $380.
The Week
Alnylam Pharma (ALNY) fell 6.55% this week to $248.68, closing well behind the S&P 500’s 0.8% decline and underperforming by about 5.75 percentage points. The week held no major catalysts. The stock rallied early, touching $272.08 intraday on Tuesday, 8 September, before slipping through the rest of the week. Thursday, 10 September, marked the week’s low around $246.01, with a modest recovery into Friday’s close. The weekly swing exceeded 10%, within a 60-day range of $197.81 to $380. The 20-day and 60-day moving averages sit at $243.89 and $261.30 respectively.
Analyst Ratings
Across 29 firms covering the stock, 22 rate it buy or overweight and 7 rate it hold, with no sell or underweight ratings. The consensus rating is buy, with a consensus target of $371.35, roughly 49.33% above the latest close. Targets range from $256 to $536, showing wide dispersion. Within a biotech peer group of 506 names, ALNY ranks 5th by analyst rating.
The Week Ahead
US macro data dominates next week. Tuesday, 15 September brings the New York Fed manufacturing index, with consensus at 14.75 versus a prior 20.6. Wednesday, 16 September features retail sales and the NAHB housing market index. Consensus for retail sales excluding autos is 0.6, up from -0.3; the NAHB index is seen at 34, slightly below the prior 35. These releases will offer fresh signals on US consumption and manufacturing momentum.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.